ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
PainReform Ltd

PainReform Ltd (PRFX)

3.19
0.20
(6.69%)
Al cierre: 26 Febrero 3:00PM
3.20
0.01
( 0.31% )
Fuera de horario: 5:00PM
Gráfico avanzado

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
3.20
Postura de Compra
3.15
Postura de Venta
3.25
Volume Operado de la Acción
59,053
2.99 Rango del Día 3.2082
1.7272 Rango de 52 semanas 61.20
Capitalización de Mercado [m]
Precio Anterior
2.99
Precio de Apertura
2.99
Última hora de negociación
16:33:57
Volumen financiero
US$ 183,821
Precio Promedio Ponderado
3.1128
Volumen promedio (3 m)
3,594,991
Acciones en circulación
556,613
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.19
Beneficio por acción (BPA)
-16.79
turnover
-
Beneficio neto
-9.34M

Acerca de PainReform Ltd

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics.

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Herzliya, Center, Isr
Fundado
-
PainReform Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRFX. The last closing price for PainReform was US$2.99. Over the last year, PainReform shares have traded in a share price range of US$ 1.7272 to US$ 61.20.

PainReform currently has 556,613 shares in issue. The market capitalisation of PainReform is US$1.66 million. PainReform has a price to earnings ratio (PE ratio) of -0.19.

PRFX Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.02-0.6211180124223.223.612.861901403.34988966CS
4-0.15-4.47761194033.355.33992.720617024653.68100382CS
120.4215.10791366912.7816.632.1635949917.47745107CS
26-3.0232-48.57950893436.223216.631.727235520816.26363985CS
52-43.84-93.197278911647.0461.21.727220349176.92821677CS
156-232-98.6394557823235.2633.841.727283312145.7376059CS
260-1597.6-99.800099951600.81881.61.7272714052222.2930774CS

PRFX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de PainReform?
El precio actual de las acciones de PainReform es US$ 3.20
¿Cuántas acciones de PainReform están en circulación?
PainReform tiene 556,613 acciones en circulación
¿Cuál es la capitalización de mercado de PainReform?
La capitalización de mercado de PainReform es USD 1.66M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de PainReform?
PainReform ha negociado en un rango de US$ 1.7272 a US$ 61.20 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de PainReform?
El ratio precio/beneficio de PainReform es -0.19
¿Cuál es la moneda de reporte de PainReform?
PainReform presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de PainReform?
El último beneficio anual de PainReform es USD -9.34M
¿Cuál es la dirección registrada de PainReform?
La dirección registrada de PainReform es 60C MEDINAT HAYEHUDIM, C/O MEDICA VP, 2ND FL, POBOX 2206, HERZLIYA, CENTER, 4676670
¿Cuál es la dirección del sitio web de PainReform?
La dirección del sitio web de PainReform es www.painreform.com
¿En qué sector industrial opera PainReform?
PainReform opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ULYUrgent ly Inc
US$ 0.8301
(97.64%)
6.18M
CPOPPop Culture Group Company Ltd
US$ 1.33
(92.20%)
9.26M
BLMZBloomZ Inc
US$ 0.49
(36.19%)
6.85M
NIXXNixxy Inc
US$ 2.11
(33.54%)
7.87M
ROOTRoot Inc
US$ 116.00
(17.52%)
114.53k
DMRCDigimarc Corporation
US$ 20.00
(-26.04%)
38.97k
SYTASiyata Mobile Inc
US$ 3.18
(-23.74%)
493.31k
SPGCSacks Parente Golf Inc
US$ 0.58
(-20.78%)
1.46M
TNDMTandem Diabetes Care Inc
US$ 27.3999
(-18.43%)
309.99k
PITAHeramba Electric PLC
US$ 0.5655
(-17.86%)
1.51M
NVDANVIDIA Corporation
US$ 130.03
(-0.95%)
40.91M
CPOPPop Culture Group Company Ltd
US$ 1.33
(92.20%)
9.26M
NIXXNixxy Inc
US$ 2.11
(33.54%)
7.87M
CLEUChina Liberal Education Holdings Ltd
US$ 0.063
(-15.21%)
7.09M
BLMZBloomZ Inc
US$ 0.49
(36.19%)
6.85M

PRFX Finanzas

Finanzas

PRFX Discussion

Ver más
glenn1919 glenn1919 1 semana hace
PRFX.........................................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
makinezmoney makinezmoney 1 semana hace
$PRFX: Yupppppppppp........... $5 breaker.

There it goes.


PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity


February 18, 2025 08:30 ET
| Source: PainReform Ltd

Share






DeepSolar brings new customer base in creation, including major utility-scale
solar operators and independent power producers, while
breaking into the residential solar market

The Company remains committed to advancing its drug delivery
technologies while broadening its growth potential

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has executed a definitive agreement with BladeRanger Ltd, a public company registered under the laws of the State of Israel, whose shares are listed for trading on Tel Aviv Stock Exchange under the ticker “BLRN” (the “BLRN”) to acquire 100% of the business activity of DeepSolar, an AI-driven solar analytics platform owned by BLRN (the “Agreement”). This strategic acquisition represents a compelling and highly opportunistic move for PainReform. At the same time, the Company remains committed to advancing its drug delivery technologies, including pain treatment and other specialty pharmaceuticals. The acquisition is expected to close before the end of February 2025, subject to the satisfaction of customary closing conditions.

DeepSolar is a cutting-edge AI-powered analytics company that optimizes the efficiency and profitability of solar energy assets. DeepSolar leverages proprietary software and AI-driven automation tools, providing a significant competitive advantage in solar energy management. Its technology integrates seamlessly with SCADA systems via a centralized dashboard, offering real-time monitoring, performance analytics, and automated maintenance solutions.

Operating in both the B2B and B2C sectors, DeepSolar provides enterprise-level solutions for large-scale solar operators and residential applications for individual homeowners. In the commercial sector, its platform helps solar farms reduce operational inefficiencies and increase energy output. In the residential market, its mobile app empowers homeowners to optimize their solar investments, detect inefficiencies, and reduce energy costs. DeepSolar’s platform can cut operational costs by up to 30% while maximizing energy production, presenting a significant market opportunity across multiple verticals.

DeepSolar is in the process of establishing a diverse customer base, including major utility-scale solar operators, independent power producers, and residential solar system owners. Its AI-driven analytics platform is trusted by large-scale energy producers to optimize portfolio performance, aiming to ensure maximum uptime and efficiency. Additionally, DeepSolar’s residential mobile app "My DeepSolar" is expected to gain traction among homeowners seeking to monitor and enhance the performance of their solar installations.

“We are incredibly excited about the unique opportunity this acquisition presents,” said Ehud Geller, Chairman of PainReform. “While at first glance, a pharmaceutical company acquiring a solar analytics business may seem unconventional, the rationale is both compelling and strategic. DeepSolar operates in a rapidly growing, high-margin sector where AI-driven solutions are revolutionizing solar energy efficiency and profitability. Given the significant potential of this opportunity, we believe this move is designed for increasing our shareholders benefit.”

PainReform identified DeepSolar as an exceptional value-creation opportunity due to its advanced AI-based software, which optimizes solar energy production through real-time monitoring, performance analytics, and automated reporting tools. According to the SolarPower Europe report on the solar market from 2021–2026, the solar energy market is expanding rapidly, generating over 1 terawatt (TW) of energy and growing at an annual rate of 25.32%. DeepSolar’s technology enhances the profitability of solar assets by reducing operational costs, maximizing energy yield, and providing predictive analytics to drive better decision-making.

Under the terms of the Agreement, PainReform will receive all rights, title and interest in certain (i) the agreements, (ii) intellectual property, (iii) accounts receivable, (iv) equipment, (v) Deep Solar’s reputation and customer relations associated with their business, (vi) the “My DeepSolar” application and platform, and (vi) all rights, title and interest in, to or arising from any of the foregoing assets, properties and rights (whether real, personal or mixed, tangible or intangible, wherever located), each as set forth or defined in the Agreement (collectively, the “Acquired Assets”). In consideration for the sale of the Acquired Assets, BLRN is entitled to receive (1) 178,769 ordinary shares of the Company, representing 9.9% of the issued and outstanding share capital of PainReform (after such issuance); (2) 223,792 pre-funded warrants to purchase 223,792 ordinary shares; (3) 685,004 pre-funded milestone warrants to purchase 685,004 ordinary shares; (4) 1,087,565 warrants-A to purchase 1,087,565 ordinary shares; and (5) 1,087,565 warrants-B to purchase 1,087,565 ordinary shares (collectively, the “Securities”). In addition, certain employees of BLRN shall enter into employment agreements with PainReform.

Pursuant to the Agreement, BLRN may not exercise any of the pre-funded warrants, pre-funded milestone warrants, warrants-A or warrants-B held by it (or any assignee or transferee of BLRN), if, following such exercise, BLRN (including any assignee or transferee) holds shares of the Company which exceed 9.99% of the issued and outstanding share capital of PainReform.

From the date of execution of the Agreement until ninety (90) days after the date of closing of the business acquisition, PainReform may not (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ordinary shares or ordinary share equivalents or (ii) file a registration statement or any amendment or supplement thereto, other than as contemplated pursuant to the Agreement. PainReform undertook to register the Securities with the Securities and Exchange Commission within sixty days from the date of the closing of the business acquisition.

Highlights of DeepSolar

AI-Driven Solar Management Platform – DeepSolar’s software provides comprehensive, real-time insights that optimize solar field productivity, offering a significant advantage over traditional legacy systems.
High-Margin, Scalable Business Model – The company’s platform-as-a-service model ensures recurring revenue, minimal overhead, and significant scaling potential in both commercial and residential solar markets.
Massive Market Opportunity – According to industry reports, the global residential solar market was valued at $94.2 billion in 2024. According to the Solar Industry Research Data report quotes, the global residential solar market alone was valued at $94.2 billion in 2024, and is estimated to grow by 8%/year until 2034
Cost-Reduction Capabilities – DeepSolar’s analytics reduce operational and maintenance (O&M) expenses by up to 30%, directly improving customers’ bottom lines.
Despite this diversification, PainReform remains committed to advancing its proprietary technologies and drug candidate focused on extended-release pain relief while exploring additional specialty pharmaceutical pipeline opportunities. The Company’s existing management team and Board of Directors remain in place, ensuring operational continuity while leveraging the financial and strategic advantages of the DeepSolar acquisition.

PainReform views this acquisition as a game-changing addition to its portfolio. By capitalizing on a rapidly growing sector with deep technological moats, the Company believes it is positioning itself for potential long-term growth while maintaining its focus on pharmaceutical innovation.

“This acquisition is about recognizing and seizing a unique opportunity that can profoundly impact our business,” added Geller. “DeepSolar’s cutting-edge analytics capabilities have the potential to position us at the forefront of a thriving industry while continuing our mission in the pharmaceutical sector.”

Additional details about the transaction are available in the Company’s Form 6-K, which has been filed with the Securities and Exchange Commission.

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. The Company's proprietary extended- release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements about PainReform’s expectations, beliefs and intentions including with respect to the anticipated benefits to PainReform of the acquisition of DeepSolar, the anticipated market opportunity, the completion of the business acquisition and the satisfaction of customary closing conditions related to the business acquisition. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: our ability to satisfy the conditions to closing the proposed transaction in the anticipated timeframe or at all; our ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; our ability to continue as a going concern, our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial product candidate, PRF-110; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile; our ability to maintain our listing on the Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business, including due to the current war in Israel. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

Dr. Ehud Geller
Chairman and interim Chief Executive Officer PainReform Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com
👍️0
glenn1919 glenn1919 4 semanas hace
PRFX......................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 1 mes hace
Sweet! GO FOR IT!♥️
👍️0
tw0122 tw0122 1 mes hace
$5.30s +'60% All aboard to $6 
👍️ 1 😵 1 🥰 1
tw0122 tw0122 1 mes hace
Offloaded half right above $4 and 
has $4.40 resistance then $4.50 to $5.60 then $11.16. 
All back out if $3.60 hits will revisit to lock all profits 
👍️0
tw0122 tw0122 1 mes hace
$4 + 23% runs to $6 hopefully minimum but $10
Is the goal
Next zone $4.40s 
Whole float trading it's not me by myself lol
👍️0
subslover subslover 1 mes hace
Did I take my own advice on this one? NO.....😰
👍️0
tw0122 tw0122 1 mes hace
New update out any time... TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
👍️0
tw0122 tw0122 1 mes hace
Another $10 move 
👍️0
tw0122 tw0122 1 mes hace
Boom boom $3.70s running 
👍️0
glenn1919 glenn1919 1 mes hace
PRFX...............................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 1 mes hace
Hit and run stock. She will make a huge quick move up at some point. Good one to buy and wait.
👍️0
tw0122 tw0122 1 mes hace
Grabbed $3s for now expanded error results one of these days could trigger nonopiod pain relief 
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
lmao..sure did clown
👍️0
Zardiw Zardiw 2 meses hace
israeli trading scam......this will crash hard...

Z
👍️0
Strukture Strukture 2 meses hace
Looks like this could run hard into close and AH
👍️0
Tool_power Tool_power 2 meses hace
No, they split on Nov 21, 2024. That’s done. I don’t see any news anywhere.
👍️0
glenn1919 glenn1919 2 meses hace
prfx....................https://stockcharts.com/h-sc/ui?s=prfx&p=W&b=5&g=0&id=p86431144783
👍️0
oldstocks oldstocks 2 meses hace
0 shares to short
https://fintel.io/ss/us/prfx
👍️0
Invest-in-America Invest-in-America 2 meses hace
PRFX: I hammered COPILOT about this, & it said PRFX (allegedly) announced a REVERSE SPLIT sometime yesterday!!!
👍️0
Tool_power Tool_power 2 meses hace
According to Yahoo Finance (take with a grain of salt), the Shares Outstanding are 874,860 which I believe is accurate from recent filings.
And the shares short % of OS is 8.86%.

That will probably increase after today unless the company releases positive news to back up this price movement.
👍️0
Tool_power Tool_power 2 meses hace
What is driving today’s price action? I don’t see any news from the company.
👍️0
subslover subslover 2 meses hace
What a shame :(😭
👍️0
subslover subslover 2 meses hace
What a shame :(😭
👍️0
oldstocks oldstocks 2 meses hace
Anyone who thinks to short this it ran to $158.46 July 10th 2023
👍️0
tw0122 tw0122 2 meses hace
$16 it is down now 
👍️0
trader59 trader59 2 meses hace
Computer generated wash trading, brazen manipulation of the PPS. The O/S has already turned over 90X's, every share changing hands, on average, 90 times and its 10:20. That isn't real and is designed to trap the naive with grossly overpriced stock.
👍️0
subslover subslover 2 meses hace
Yup. Sometimes it pays to bottom-sit these babies!
👍️0
tw0122 tw0122 2 meses hace
Low floaters in action 
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
PRFX what a repeat offender
👍️0
subslover subslover 2 meses hace
The stock has a case of the runs!😷
👍️0
glenn1919 glenn1919 2 meses hace
PRFX.......................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 meses hace
prfx............................https://stockcharts.com/h-sc/ui?s=prfx&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 meses hace
PRFX...$5.44...Volume still pouring in here...🥳off my $4.02 Alert...

georgie18

Member Level
Re: georgie18 post# 266

Thursday, December 05, 2024 7:48:43 AM

Post#
271
of 271
PRFX...$6.44...Off my $4.02 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 386454

Wednesday, December 04, 2024 4:25:52 PM

Post#
386456
of 386485
PRFX...$4.50s clearing here...🥳off the $4.02 Alert...

georgie18

Member Level
Re: None

Wednesday, December 04, 2024 4:19:19 PM

Post#
264
of 265
PRFX...$4.02...Small Floater getting traction here...🥳
👍️0
georgie18 georgie18 3 meses hace
PRFX...$6.44...Off my $4.02 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 386454

Wednesday, December 04, 2024 4:25:52 PM

Post#
386456
of 386485
PRFX...$4.50s clearing here...🥳off the $4.02 Alert...

georgie18

Member Level
Re: None

Wednesday, December 04, 2024 4:19:19 PM

Post#
264
of 265
PRFX...$4.02...Small Floater getting traction here...🥳
👍️0
glenn1919 glenn1919 3 meses hace
PRFX.....................................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 meses hace
Looking good $6.58 + 147%. 🚀🚀
👍️0
subslover subslover 3 meses hace
Freegin crazy! $7.01 and hit $8.00 all in pre mkt
👍️0
subslover subslover 3 meses hace
$4.29 on this === On December 4, 2024, Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rules for continued listing.
👍 1 🚀 1
georgie18 georgie18 3 meses hace
PRFX...$4.50s clearing here...🥳off the $4.02 Alert...

georgie18

Member Level
Re: None

Wednesday, December 04, 2024 4:19:19 PM

Post#
264
of 265
PRFX...$4.02...Small Floater getting traction here...🥳
👍 1 🚀 1
glenn1919 glenn1919 3 meses hace
PRFX...................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍 1 🚀 1
georgie18 georgie18 3 meses hace
PRFX...$4.02...Small Floater getting traction here...🥳
👍 1 🚀 1
tw0122 tw0122 3 meses hace
$3.14 +10% Phase 3 looks ok. Some ambiguity still on post result treatment but if you error on the slightly positive side for resultsva 500% gainer with the 500k float 
👍 1 🚀 1
glenn1919 glenn1919 3 meses hace
PRFX..............................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍 1 🚀 1
glenn1919 glenn1919 3 meses hace
PRFX......................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍 1 🚀 1
glenn1919 glenn1919 3 meses hace
PRFX........................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍 1 🔥 1
benyam benyam 3 meses hace
where the hell all share s came from if reverse stock split will happen and outstanding share will bbee less pne one milly available
👍️0
glenn1919 glenn1919 3 meses hace
PRFX.................................https://stockcharts.com/h-sc/ui?s=PRFX&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 3 meses hace
PainReform Ltd. (the “Company”) is announcing that it will effect a reverse share split of the Company’s ordinary shares after market close on Wednesday, November 20, 2024, at the ratio of 1-for-4, such that each four (4) ordinary shares, no par value, shall be consolidated into one (1) ordinary share, no par value. The first date when the Company’s ordinary shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Thursday, November 21, 2024.

Following the implementation of the reverse split, the Company’s authorized share capital shall be comprised of 2,500,000 ordinary shares, no par value per share, and approximately 590,616 ordinary shares shall be issued and outstanding.

No fractional ordinary shares will be issued as a result of the reverse split. All fractional ordinary shares will be rounded up to the nearest whole ordinary share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase ordinary shares.
👍 1 🚀 1

Su Consulta Reciente

Delayed Upgrade Clock